

CONGRATULATIONS!

CHU de Quebec - Université Laval is now activated.



Thank you for enrolling patients with COVID-19 into LOVIT. As of April 6, we have enrolled 22 COVID-19 patients at 6 hospitals.

Sites	# patients enrolled with COVID-19 suspected or confirmed at baseline
CIUSSS de l'Estrie - CHUS	8
Sunnybrook	4
CHUM	3
Ottawa General Hospital	3
Juravinski Hospital	2
Ottawa Civic Hospital	2

LOVIT - FAQ

Question: Are patients with COVID-19 (suspected of or confirmed) eligible to participate in LOVIT?

Answer: Yes, patients with sepsis from bacterial or viral (influenza, COVID-19) sources are eligible.

Question: How should samples be handled and processed for LOVIT participants with suspected or confirmed COVID-19?

Answer: Please follow local institutional guidelines and recommendations for processing samples. The WHO recommends that samples from COVID-19 patients be manipulated in a level 2 confinement room.

Question: A patient is admitted to the ICU for sepsis and does not receive vasopressors upon admission. A few hours after ICU admission, the patient is sedated and requires vasopressor infusion. Is this patient eligible for LOVIT?

Answer: Yes, this patient is eligible for LOVIT as they receive vasopressors and is within 24 hours of ICU admission. To be eligible, the patient must be on vasopressors at the time of randomization.


Question: During the pandemic, how can treating clinicians minimize the number of glucose measurements in patients who are receiving IV insulin?

Answer: While not mandated by the LOVIT protocol, the treating clinicians may instead prescribe subcutaneous insulin. This will reduce the need for hourly glucose measurements.



StatStrip Glucometer Error #9

Two sites recently reported an "error #9" reading on their StatStrip glucometers for two LOVIT participants. This error message means that there is something in the blood sample that does not allow the StatStrip device to measure the glucose level. If you encounter this error message, please report it as an Adverse Event (Form 7) in iDataFax. The Coordinating Centre will report all problems to NovaBiomedical, which manufactures the device.

Recruitment as of March 31, 2020




Data Validation Summary by Site (as of March 31, 2020)



Sites	In progress	Activated	# patients enrolled in March 2020	# patients enrolled
CIUSSS de l'Estrie - CHUS			13	150
Juravinski Hospital		17-APR-2019	1	42
Ottawa General Hospital		17-JUL-2019	5	38
Kingston HSC		27-FEB-2019		26
Ottawa Civic Hospital		17-JUL-2019	3	17
CHUM		05-APR-2019	3	16
CISSS Chaudière-Appalaches		05-APR-2019		15
Sunnybrook HSC		12-SEP-2019	6	13
St. Joseph's Healthcare		23-AUG-2019	2	10
Hamilton General Hospital		26-APR-2019	2	8
IUCPQ		01-MAR-2019		7
University of Alberta		17-JUL-2019		7
Mount Sinai Hospital		04-DEC-2019	1	6
Trois-Rivières (CIUSSS MCQ)		15-JUL-2019		5
Hôpital Sacré-Cœur		26-JUL-2019		5
Victoria (VIHA)		26-NOV-2019		4
Royal Alexandra Hospital		24-JAN-2020	1	3
McGill (RVH)		09-JUL-2019		2
Maisonneuve-Rosemont		17-APR-2019		2
McGill (MGH)		09-JUL-2019		1
CHU de Quebec - Univ. Laval		31-MAR-2020		
Regina General Hospital	✓			
St. Michael's Hospital	✓			
London HSC	✓			
Humber River Hospital	✓			
Vitalité, New Brunswick	✓			
Apollo Hospital, India	✓			
Auckland City Hospital, New Zealand	✓			
Christchurch Hospital, New Zealand	✓			
Tauranga Hospital, New Zealand	✓			
Wellington Regional Hospital, New Zealand	✓			
Rabin Medical Center, Israel	✓			
King Abdullah International Medical Research Center, Saudi Arabia	✓			
Raymond Poincaré University Hospital, France	✓			

There were 37 patients enrolled into LOVIT in March 2020.

Thanks for your constant efforts!



PLEASE CONTACT US IF YOU HAVE QUESTIONS ABOUT THE LOVIT TRIAL

Marie-Hélène Masse
Project leader

1-819-346-1110 ext. 14173
marie-helene.masse3@usherbrooke.ca

Julie Ménard
Co-Project leader

1-819-346-1110 ext. 13534
julie.menard.ciussse-chus@ssss.gouv.qc.ca

Visit our website: <http://lovit.ccctg.ca/>